Tag:
Chimerix
Latest Headlines
Latest Headlines
Biotech Chimerix shines in IPO debut as interest grows in antiviral drugs
The Durham, NC-based drug developer's stock soared on its first day of trading, with an initial price of $14 per share that shot up 34% to $18.79 per share by the end of the day.
Chimerix, Omthera enter price ranges for expected biotech IPOs
Two biotech players have offered price ranges for their hoped-for initial public offerings. Chimerix aims to sell 6.1 million shares for between $13 and $15 per share, and Omthera has priced its IPO shares in the $12 to $14 range.
Biotech Chimerix reveals ex-Pharmasset recruit after unveiling $85M IPO plan
As the biotech advances its lead antiviral drug to Phase III development, Chimerix has tapped a veteran of one of the most high-profile pharma R&D programs in the world.
Ariad lands Jonathan E. Dickinson as general manager, Europe
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Jennifer Levin ( email | Twitter ) and we will feature it...
UPDATED: Merck snags Chimerix antiviral HIV program in $168.5M deal
Research Triangle Park, NC-based Chimerix has inked its first big partnership, reaping a $17.5 million upfront payment and a promise of up to $151 million more from Merck, which gains rights to a mid-stage antiviral--CMX157--which has prospects as a new addition to future HIV cocktails.
Chimerix funds antiviral drug work with $45M round
With two antiviral drug candidates in the clinic, Durham, NC-based Chimerix has raised $45 million in a Series F round of financing. New Leaf Venture Partners led the round. The firm was joined by
SIGA gets nod for $2.8B antiviral contract, shares rocket up
SIGA Technologies says it has been selected to deliver a smallpox antiviral drug to the nation's biodefense stockpile, landing a contract which is worth $500 million at the base level and zooms all
VC insiders inject $16M into Chimerix
With an experimental antiviral in mid-stage clinical trials, Research Triangle Park, NC-based Chimerix has raised $16.1 million from a Series E. Canaan Partners, Alta Partners, Sanderling Ventures
Scientists ID compound that may work against adenovirus
Scientists at Saint Louis University School of Medicine say that an experimental therapy being tested by Durham, NC-based Chimerix may become the first candidate for human trials for adenovirus.
